SINCO PHARMA (06833) · Company profile · Eqvero

SINCO PHARMA

06833HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	2.08 bn CNY	2.82 bn CNY	2.54 bn CNY	2.27 bn CNY	2.02 bn CNY
Cost of revenue	1.84 bn CNY	2.5 bn CNY	2.2 bn CNY	1.95 bn CNY	1.65 bn CNY
Research and development expense	2.68 m CNY	19 m CNY	8.29 m CNY	11.27 m CNY	26.16 m CNY
Selling, general and administrative expense	140.32 m CNY	189.92 m CNY	202.58 m CNY	198.44 m CNY	171.38 m CNY
Operating profit after depreciation	74.68 m CNY	113.95 m CNY	116.46 m CNY	101.22 m CNY	192.55 m CNY
Operating profit before depreciation	100.26 m CNY	138.44 m CNY	132.78 m CNY	112.58 m CNY	199.25 m CNY
EBIT	74.68 m CNY	113.95 m CNY	116.46 m CNY	101.22 m CNY	192.55 m CNY
EBITDA	100.26 m CNY	138.44 m CNY	132.78 m CNY	112.58 m CNY	199.25 m CNY
Interest expense	15.37 m CNY	12.55 m CNY	9.81 m CNY	13.81 m CNY	21.45 m CNY
Profit before tax	48.26 m CNY	98.92 m CNY	99.88 m CNY	99.29 m CNY	167.39 m CNY
Income tax expense	13.41 m CNY	56.88 m CNY	57.53 m CNY	29.83 m CNY	32.3 m CNY
Income before extraordinary items	34.85 m CNY	42.05 m CNY	42.35 m CNY	69.46 m CNY	135.08 m CNY
Common dividends	3.06 m CNY	3.76 m CNY	7.26 m CNY	17.69 m CNY	—
Total dividends	3.06 m CNY	3.76 m CNY	7.26 m CNY	17.69 m CNY	—

Quotes are end-of-day data. Content is for research purposes and is not investment advice.